With less than 5% of all cancer patients enrolling in clinical trials, how are you adapting your trial design to get the most out of your trial and speed time to market?

Other challenges include issues such as validating biomarkers, establishing appropriate endpoints (overall outcome that the protocol is designed to evaluate - common endpoints are severe toxicity, disease progression, or death) and data capturing.

The 2nd Annual Optimising Clinical Development in Oncology conference will provide you with a great opportunity to discuss various trial designs, patient recruitment and retention strategies and biomarker validation. Find out how others are tackling the main challenges, through a variety of presentations, workshops and interactive learning opportunities - network with your peers and forge new contacts.